MediWound Ltd. (NASDAQ:MDWD) Receives Average Recommendation of “Hold” from Brokerages

Shares of MediWound Ltd. (NASDAQ:MDWD) have been assigned a consensus recommendation of “Hold” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $32.25.

Several equities research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Wednesday, October 8th. Wall Street Zen cut shares of MediWound from a “hold” rating to a “sell” rating in a research report on Friday, July 18th. Finally, Zacks Research cut shares of MediWound from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th.

Institutional Trading of MediWound

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Meitav Investment House Ltd. raised its position in MediWound by 825.7% in the 3rd quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company’s stock worth $5,241,000 after purchasing an additional 260,116 shares during the period. Silverberg Bernstein Capital Management LLC raised its position in MediWound by 17.1% in the 3rd quarter. Silverberg Bernstein Capital Management LLC now owns 172,816 shares of the biopharmaceutical company’s stock worth $3,114,000 after purchasing an additional 25,281 shares during the period. ARK Investment Management LLC raised its position in MediWound by 6.7% in the 1st quarter. ARK Investment Management LLC now owns 106,930 shares of the biopharmaceutical company’s stock worth $1,660,000 after purchasing an additional 6,684 shares during the period. The Manufacturers Life Insurance Company raised its position in MediWound by 104.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock worth $505,000 after purchasing an additional 13,312 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in MediWound by 17.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 22,468 shares of the biopharmaceutical company’s stock worth $349,000 after purchasing an additional 3,343 shares during the period. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Stock Performance

Shares of MDWD opened at $18.32 on Tuesday. The company’s fifty day moving average is $17.77 and its 200 day moving average is $18.83. MediWound has a fifty-two week low of $14.14 and a fifty-two week high of $22.50. The stock has a market capitalization of $203.11 million, a PE ratio of -6.94 and a beta of 0.27.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.68). MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.The business had revenue of $5.71 million during the quarter, compared to the consensus estimate of $5.68 million. As a group, research analysts forecast that MediWound will post -2.66 earnings per share for the current year.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.